Derek Lowe's commentary on drug discovery and the pharma industry. An editorially independent blog from the publishers of Science Translational Medicine. All content is Derek’s own, and he does not in any way speak for his employer.
I mentioned yesterday in my post about anti-vaccine arguments that there seemed to be suspicions on social media platforms about vaccine testing in Africa. I’ve been looking around for more of that, and finding plenty of it. I’ve also heard from a colleague with some pertinent thoughts about how these things get going, and I… Read More
Among the many drug-discovery lessons that this pandemic is highlighting is the difficulty of meeting the challenges of a new target, a new pathogen, a new disease, or a new mechanism of action. When you look at the history of the drug industry, the typical time for an effective therapy to be developed from a… Read More
Now that chloroquine is in the news everywhere, I thought it might be interesting to have a closer look at the compound. The first part of this post will be chemistry-heavy, further down we’ll get into the pharmacology and medical uses. Chloroquine’s fame is as an antimalarial drug, and the history of antimalarials starts of… Read More
I’m sitting in an MIT conference on AI in drug discovery/development as I write this. One of the speakers here (Mathai Mammen, J&J/Janssen) just made a good point – not a new one, but a solid one that deserves some thought. He called for “bilingual” people, by which he means people who have some fluency… Read More
Many roots of organic chemistry, and of medicinal chemistry in particular, often originate in what might seem like an unlikely place: the dyestuff industry of the late 19th century. I had already known this to some degree, but writing the historical vignettes in The Chemistry Book really brought it home to me. And if you… Read More
Here’s a useful article that looks at the fate of university-licensed startup (ULS) life sciencecompanies over the last few years. There are more and more such companies (a greater than tenfold increase in their number since 1990), but a comprehensive look at success rates (and how such rates vary according to the universities involved) has… Read More
It’s time to talk about a new venture called EQRx. This has made quite a splash in the last few days at the JP Morgan investor conference, and it’s been launched by Alexis Borisy (involved with founding and/or helping run CombinatoRx, Foundation, Blueprint, WarpDrive Bio, Editas, Relay and others) with the aim of generating cheaper… Read More
I mentioned cancer incidence versus cancer mortality the other day, and I wanted to highlight this NEJM paper, which is a recent and comprehensive look at the topic. You can see several different effects in the data. Hodgkin’s lymphoma, for example, has shown a pretty steady incidence rate over the past 40 years, but steadily… Read More
I mentioned polymorphs the other day, and no mention of those should go by without a reference to the classic 1995 article on “disappearing polymorphs” and its 2015 follow-up. This is a controversial area, but what everyone can agree on is that there are numerous cases where some particular crystal form of a compound has… Read More
We’re seeing a lot of bivalent molecules in drug discovery these days, especially with the popularity of bifunctional protein degrader ligands. The general structure of such thing is (ligand)—-linker—-(ligand), with the two ligands chosen (in the case of targeted protein degradation) to bring a ubiquitin ligase complex up close to… Read More
